Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 24, Issue 6, 2006, Pages 636-642

  Laivoranta Nyman, Susanna ^a,j   Möttönen, Timo ^b   Hannonen, Pekka ^c   Korpela, Markku ^d   Kautiainen, Hannu ^e   Leirisalo Repo, Marjatta ^f   Julkunen, Heikki ^g   Luukkainen, Reijo ^h   Hakala, Markku ⁱ   Vuori, Kaisa ^b   Laine, Antti Pekka ^a   Toivanen, Auli ^b   ILonen, J ^a   Ahonen, Jari ^k   Blåfield, Harri ^k   Franzen, Per ^k   Forsberg, Sinikka ^k   Friman, Claes ^k   Griepenberg Gahmberg, Marianne ^k   Hakola, Mikko ^k   Helve, Tapani ^k   Ilva, Kirsti ^k   Järvinen, Pentti ^k   Kaipiainen Seppänen, Oili ^k   Karjalainen, Anna ^k   Koivisto, Olli ^k   Koota, Kalevi ^k   Koski, Juhani ^k   Laasonen, Leena ^k   Luosu Järvi, Riitta ^k   Nissilä, Martti ^k   Paimela, Leena ^k   Piirainen, Heikki ^k   Puolakka, Kari ^k   Pälvimäki, Ilppo ^k   Yli Kerttula, Urpo ^k   more..

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g PEIJAS HOSPITAL   (Finland)

^h Central Hospital of Satakunta   (Finland)

ⁱ UNIVERSITY OF OULU   (Finland)

^j NONE   (Finland)

^k NONE

more..

Author keywords

Genetics; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FINLAND; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MICROSATELLITE MARKER; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 33846426819     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. MASI AT: Articular patterns in the early course of rheumatoid arthritis. Am J Med 1983; 75: 16-26.
2. MÖTTÖNEN T, HANNONEN P, KORPELA M et al.: Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894-8.
3. PINCUS T, SOKKA T, KAUTIAINEN H: Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005; 52: 1009-19.
4. PINCUS T, O'DELL JR, KREMER JM: Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Int Med 1999; 131: 768-74.
5. MÖTTÖNEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999; 353: 1568-73.
6. MACGREGOR A, OLLIER W, THOMSON W, JAWAHEER D, SILMAN A: HLA-DRB1 *0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol 1995; 22: 1032-6.
7. MCDONAGH JE, DUNN A, OLLIER WE, WALKER DJ: Compound heterozygosity for the shared epitope and the risk and severity of rheumatoid arthritis in extended pedigrees. Br J Rheumatol 1997; 36: 322-7.
8. HALL FC, WEEKS DE, CAMILLERI JP et al.: Influence of the HLA-DRB1 locus on susceptibility and severity in rheumatoid arthritis. Q J Med 1996; 89: 821-9.
9. BRENNAN FM, MAINI RN, FELDMANN M: TNF α-a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31: 293-8.
10. AREND WP, DAYER JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-60.
11. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
12. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
13. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
14. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36: 1681-90.
15. KREMER JM: Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001; 134: 695-706.
16. CARROLL MC, KATZMAN P, ALICOT EM et al.: Linkage map of the human major histo-compatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci U S A 1987; 84: 8535-9.
17. NEDOSPASOV SA, UDALOVA IA, KUPRASH DV, TURETSKAYA RL: DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNF-β) gene. J Immunol 1991; 147: 1053-9.
18. JONGENEEL CV, BRIANT L, UDALOVA IA, SEVIN A, NEDOSPASOV SA, CAMBON-THOMSEN A: Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. Proc Natl Acad Sci U S A 1991; 88: 9717-21.
19. UDALOVA IA, NEDOSPASOV SA, WEBB GC, CHAPLIN DD, TURETSKAYA RL: Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 1993; 16: 180-6.
20. POCIOT F, BRIANT L, JONGENEEL CV et al.: Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23: 224-31.
21. BENDTZEN K, MORLING N, FOMSGAARD A et al.: Association between HLA-DR2 and production of tumour necrosis factor α, and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand J Immunol 1988; 28: 599-606.
22. JACOB CO, FRONEK Z, LEWIS GD, KOO M, HANSEN JA, MCDEVITT HO: Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α: Relevance to genetic predisposition to systemic lupus erytematosus. Proc Natl Acad Sci USA 1990; 87: 1233-7.
23. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
24. PREVOO ML, van't HOF MA, KUPER HH, van LEEUWEN MA, van de PUTTE LB, van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
25. PINALS RS, MASI AT, LARSEN RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
26. TUOKKO J, KOSKINEN S, WESTMAN P, YLI-KERTTULA U, TOIVANEN A, ILONEN J: Tumour necrosis factor microsatellites in reactive arthritis. Br J Rheumatol 1998; 37: 1203-6.
27. OLERUP O, ZETTERQUIST H: HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-35.
28. LARSEN A, DALE K, EEK M: Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagnosis 1977; 18: 481-91.
29. ANDERSON JJ, WELLS G, VERHOEVEN AC, FELSON DT: Factors predicting response to treatment in rheumatoid arthritis - The importance of disease duration. Arthritis Rheum 2000; 43: 22-9.
30. MUGNIER B, BALANDRAUD N, DARQUE A, ROUDIER C, ROUDIER J, REVIRON D: Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1849-52.
31. MARTINEZ A, SALIDO M, BONILLA G et al.: Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004; 50: 1077-82.
32. MOLENAAR ETH, VOSKUYL AE, VAN DER HORST BRUINSMA IE, SCHREUDER GMT, ZANELLI E, DIJKMANS BAC: Influence of HLA polymorphism on persistent remission in rheumatoid arthritis. Ann Rheum Dis 2002; 61: 351-3.
33. MATTEY DL, HASSELL AB, DAWES PT, OLLIER WER, HAJEER A: Interaction between tumor necrosis factor microsatellite polymorphisms and the HLA-DRB1 shared epitope in rheumatoid arthritis - Influence on disease outcome. Arthritis Rheum 1999; 42: 2698-704.
34. WEYAND CM, HICOK KC, CONN DL, GORONZY JJ: The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992; 117: 801-6.
35. IOANNIDIS JPA, TARASSI K, PAPADOPOULOS IA et al.: Shared epitopes and rheumatoid arthritis: disease associations in Greece and meta-analysis of Mediterranean European populations. Semin Arthritis Rheum 2002; 31: 361-70.
36. MATTEY DL, HASSELL AB, PLANT MJ et al.: The influence of HLA-DRB1 alleles encoding the DERAA amino acid motif on radiological outcome in rheumatoid arthritis. Rheumatol 1999; 38: 1221-7.
37. HARRISON B, THOMSON W, SYMMONS D et al.: The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis Rheum 1999; 42: 2174-83.
38. MÖTTÖNEN T, PAIMELA L, LEIRISALO-REPO M, KAUTIAINEN H, ILONEN J, HANNONEN P: Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis 1998; 57: 533-9.
39. van JAARSVELD CH, OTTEN HG, JACOBS JW, KRUIZE AA, BRUS HL, BIJLSMA JW: Association of HLA-DR with susceptibility to and clinical expression of rheumatoid arthritis: re-evaluation by means of genomic tissue typing. Br J Rheumatol 1998; 37: 411-6.
40. EBERHARDT K, FEX E, JOHNSON U, WOLLHEIM FA: Associations of HLA-DRB and - DQB genes with two and five year outcome in rheumatoid arthritis. Ann Rheum Dis 1996; 55: 34-9.
41. SILMAN AJ, REEBACK J, JARAQUEMADA D: HLA-DR4 as a predictor of outcome three years after onset of rheumatoid arthritis. Rheumatol Int 1986; 6: 233-5.
42. PAIMELA L, LEIRISALO-REPO M, HELVE T, KOSKIMIES S: The prognostic value of HLA DR4 and B27 antigens in early rheumatoid arthritis. Scand J Rheumatol 1993; 22: 220-4.
43. WAGNER U, KALTENHAUSER S, SAUER H et al.: HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997; 40: 341-51.
44. van ZEBEN D, HAZES JMW, ZWINDERMAN AH et al.: Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum 1991; 34: 822-30.
45. NEPOM GT: Major histocompatibility complex-directed susceptibility to rheumatoid arthritis. Adv Immunol 1998; 68: 315-32.
46. WINCHESTER R: The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994; 56: 389-466.
47. van der BERG WB, van RIEL PL: Uncoupling of inflammation and destruction in rheumatoid arthritis: myth or reality? Arthritis Rheum 2005; 52: 1020-30.
48. SMOLEN JS, HAN C, BALA M et al.: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52: 995-9.
49. HAJEER AH, DABABNEH A, MAKKI RF et al.: Different gene loci within the HLA-DR and TNF regions are independently associated with susceptibility and severity in Spanish rheumatoid arthritis patients. Tissue Antigens 2000; 55: 319-25.